# Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00004052** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** QS21
- **BIOLOGICAL:** bcr-abl peptide vaccine

## Key facts

- **NCT ID:** NCT00004052
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2013-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004052, "Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*